Atara bio tab-cel
WebNov 15, 2024 · Tab-cel has been safe and well-tolerated in >180 pts with EBV + PTLD, with tumor flare reaction (TFR) as the only identified risk (Atara Bio, Data on file). We previously presented data from ALLELE (NCT03394365) - a Phase 3, multicenter, open-label, global, registrational study - in 38 tab-cel-treated pts with EBV + PTLD following HCT or SOT ... WebFeb 8, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for …
Atara bio tab-cel
Did you know?
WebDec 14, 2024 · Overall, tab-cel was well-tolerated in treatment-refractory and immunocompromised patients. Atara also reported combined long-term survival data from Phase 2 and multicenter EAP studies of tab-cel in a second oral presentation. Results show that across studies, patients who responded to tab-cel for treatment of EBV+ PTLD … WebSep 27, 2024 · Tab-cel also has Orphan Drug status in Europe and was previously granted PRIME designation by the EMA. Following recent successful interactions with the EMA, Atara has completed the necessary regulatory and compliance steps needed to submit an MAA for tab-cel, which is on track for submission in November 2024.
WebDec 19, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for … WebNov 4, 2024 · Atara will present additional data on tab-cel and PTLD through several abstracts, including a second oral presentation on long term OS from Phase 2 and multicenter EAP studies with tab-cel in relapsed/refractory EBV+ PTLD showing median OS of 54.6 months in all patients and OS at two years reaching over 86% in responders …
WebMar 15, 2024 · Atara Bio presents Phase 2 tab-cel data in Epstein-Barr virus-driven PTLD Mar. 15, 2024 12:16 AM ET Atara Biotherapeutics, Inc. (ATRA) By: Mamta Mayani , SA News Editor 1 Comment WebDec 1, 2024 · 1 December 2024. Atara Bio has announced that the EMA has fully validated the Marketing Authorisation Application (MAA) for tabelecleucel (tab-cel®), and is the first regulatory agency in the world to review an off-the-shelf allogeneic T-cell therapy. Tab-cel has been described as an investigational treatment for patients with Epstein-Barr ...
WebMar 15, 2024 · Atara Biotherapeutics ( NASDAQ: ATRA) announces a combined long-term overall survival (OS) analysis from clinical study of tabelecleucel (tab-cel) in patients with …
WebDec 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... flame thrower bedwarsWebOct 4, 2024 · Atara will retain full rights to tab-cel ® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will … flamethrower bedwars kitWebTab-cel®, Atara's most advanced T-cell immunotherapy in development, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated … can ping with ip but not hostnameWebSep 18, 2024 · This is a multicenter, multicohort, open label, single-arm, Phase 2 study to assess the efficacy and safety of tabelecleucel for the treatment of EBV-associated … flamethrower battalionflamethrower bikiniWebJun 7, 2024 · All SOT recipients with EBV + PTLD R/R to rituximab as monotherapy or combined with chemotherapy were treated with tabelecleucel, receiving a median (range) of 2.0 (1-9) cycles. Atara has previously shown benefit in patients with EBV + PTLD after SOT who responded to tab-cel, including up to 100 percent two-year survival rates 1,2.Data … flamethrower bannedWebDec 14, 2024 · Patients who responded to tab-cel survived longer than the non-responders, with a one-year survival rate of 89.2% in the responder group versus 32.4% in the group … flamethrower black 2